Abstract
Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of Crohns disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms trigger an event, leading to the activation of an intestinal immune response. Immune and non-immune cells create a cross talk via the secretion of soluble mediators and expression of cell adhesion molecules, resulting in further cell activation. Mediators such as cytokines and chemokines play a role in cell recruitment and polarization, intercellular signal amplification or activation and differentiation. Considering these aspects, medical management of inflammatory bowel disease has changed considerably over the past decade. Advances in biotechnology has allowed for the introduction of many biologic therapies, other than anti-TNF therapies. Many of these drugs showed clinical benefit for induction and maintenance therapy, both in UC and CD. Although numerous, at present only monoclonal anti-TNF antibodies are currently available worldwide. Other biological agents have been tested or are under evaluation. This paper systematically reviews the mechanism-of-action, efficacy, short-term and, where available, long-term safety of biological agents that have been approved for the treatment of IBD or are under evaluation which target different molecules other than tumor necrosis factor α (TNF-α).
Current Drug Targets
Title: Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Volume: 11 Issue: 2
Author(s): Gionata Fiorino, Serena Rovida, Carmen Correale, Alberto Malesci and Silvio Danese
Affiliation:
Abstract: Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of Crohns disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms trigger an event, leading to the activation of an intestinal immune response. Immune and non-immune cells create a cross talk via the secretion of soluble mediators and expression of cell adhesion molecules, resulting in further cell activation. Mediators such as cytokines and chemokines play a role in cell recruitment and polarization, intercellular signal amplification or activation and differentiation. Considering these aspects, medical management of inflammatory bowel disease has changed considerably over the past decade. Advances in biotechnology has allowed for the introduction of many biologic therapies, other than anti-TNF therapies. Many of these drugs showed clinical benefit for induction and maintenance therapy, both in UC and CD. Although numerous, at present only monoclonal anti-TNF antibodies are currently available worldwide. Other biological agents have been tested or are under evaluation. This paper systematically reviews the mechanism-of-action, efficacy, short-term and, where available, long-term safety of biological agents that have been approved for the treatment of IBD or are under evaluation which target different molecules other than tumor necrosis factor α (TNF-α).
Export Options
About this article
Cite this article as:
Fiorino Gionata, Rovida Serena, Correale Carmen, Malesci Alberto and Danese Silvio, Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309975
DOI https://dx.doi.org/10.2174/138945010790309975 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Allergy After Inhalation and Ingestion of Cereals Involve Different Allergens in Allergic and Celiac Disease
Recent Patents on Inflammation & Allergy Drug Discovery Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Prevalence of Intestinal Parasites among Patients with Chronic Urticaria in Northern Iran
Infectious Disorders - Drug Targets Basophil Activation Test with Indomethacin to Assess Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs: A Preliminary Study
Inflammation & Allergy - Drug Targets (Discontinued) Symptoms, Diagnosis, and Treatment of Cow's Milk Allergy
Current Pediatric Reviews Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Hypertension in Hemodialysis Patients
Current Hypertension Reviews Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) Editorial
Current Enzyme Inhibition Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets Pharmacogenetic Determinants of Immediate and Delayed Reactions of Drug Hypersensitivity
Current Pharmaceutical Design Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach
Current Vascular Pharmacology Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) An Update on the Immunological, Metabolic and Genetic Mechanisms in Drug Hypersensitivity Reactions
Current Pharmaceutical Design Drugs in Pediatric Ischemic Stroke
Current Drug Targets